Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

The menopause market is projected to increase at a CAGR of 5.10% between 2025 – 2033, with North America making up 4.9% ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a ...

Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...